Discussion
AML
REMISSIONS, AML
According to one clinical study, patients with Gilteritinib is an oral FLT3/AXL inhibitor, which has been evaluated in a single-agent phase-I/II study [Quizartinib was evaluated in a phase III randomized, controlled clinical trial (QuANTUM-R), which was conducted in patients with Thus, both studies showed dismal and similar outcomes beyond 24 months in both the Currently, there is no commonly accepted standard for salvage chemotherapy treatment [Several studies indicate a very low probability for achieving a second CR with standard intensive salvage therapy in patients exhibiting a We designed a randomized phase-II study to compare quizartinib as adjunct to intensive salvage therapy to salvage therapy alone in terms of CR/CRi/CRh achievement using a threshold crossing approach with matched historical controls based on individual participant data from available datasets [One of the current challenges in AML treatment is finding effective and well-tolerated post-remission therapies to produce lasting or permanent remissions after achieving a CR since this could lead to a reduction in relapse that is known to be significantly high in this group of patients. Regarding the use and efficacy of maintenance therapy with Thus, the second objective of this study is to compare in a randomized manner the efficacy of prophylactic quizartinib therapy to MRD-triggered preemptive continuation therapy with quizartinib in terms of event-free survival. To our knowledge, no study so far has evaluated prophylactic maintenance with quizartinib vs. MRD-triggered continuation quizartinib-therapy.
